Eli Lilly's VERVE-102 shows promise as one-time cholesterol fix

Eli Lilly's Heart-2 trial reveals a single dose of gene-editing therapy VERVE-102 cuts LDL cholesterol by up to 62%. By safely deactivating the PCSK9 gene, it offers a potential one-time treatment for severe hypercholesterolemia. Phase 2 trials begin in late 2026, signaling a major shift from daily pills to lifelong cardiovascular care.